The global cell therapy market was valued at $5.88 billion in 2024 and is on track to hit $44.39 billion by 2034, expanding at a striking 22.69% CAGR. Researchers credit this explosive growth to record investments in R&D and rapid-fire breakthroughs in biotechnology. In little more than a decade, gene editing has evolved from a Nobel Prize-winning discovery into a commercial force unlocking new hope for tough-to-treat diseases.
CRISPR Therapeutics has become a key name in this revolution, earning a historic first FDA approval for a CRISPR-based therapy and steadily expanding its scientific reach. Now, with its ex vivo and in vivo breakthroughs attracting headlines, CRSP stock is the subject of serious market whispers. Talk of a potential takeover has sent shares rallying, as investors bet on just how pivotal this moment could be.
